Wall Street brokerages expect Tetraphase Pharmaceuticals Inc. (NASDAQ:TTPH) to report earnings per share of ($0.41) for the current fiscal quarter, Zacks Investment Research reports. Three analysts have made estimates for Tetraphase Pharmaceuticals’ earnings, with estimates ranging from ($0.47) to ($0.33). Tetraphase Pharmaceuticals reported earnings per share of ($0.79) in the same quarter last year, which would indicate a positive year over year growth rate of 48.1%. The business is expected to issue its next quarterly earnings report on Thursday, May 3rd.
According to Zacks, analysts expect that Tetraphase Pharmaceuticals will report full-year earnings of ($1.58) per share for the current year, with EPS estimates ranging from ($1.86) to ($1.21). For the next financial year, analysts anticipate that the company will report earnings of ($1.24) per share, with EPS estimates ranging from ($1.82) to ($0.96). Zacks’ EPS calculations are an average based on a survey of research analysts that follow Tetraphase Pharmaceuticals.
Tetraphase Pharmaceuticals (NASDAQ:TTPH) last released its quarterly earnings results on Thursday, March 8th. The biopharmaceutical company reported ($0.46) earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.64) by $0.18. Tetraphase Pharmaceuticals had a negative return on equity of 90.75% and a negative net margin of 1,187.17%. The business had revenue of $2.53 million during the quarter, compared to analyst estimates of $2.26 million.
Shares of Tetraphase Pharmaceuticals stock opened at $3.18 on Wednesday. Tetraphase Pharmaceuticals has a 52 week low of $2.05 and a 52 week high of $8.75. The stock has a market capitalization of $158.91, a PE ratio of -1.21 and a beta of 2.61.
In other news, insider Jacques Dumas sold 8,750 shares of the business’s stock in a transaction dated Tuesday, January 30th. The stock was sold at an average price of $6.22, for a total value of $54,425.00. Following the transaction, the insider now directly owns 8,750 shares in the company, valued at $54,425. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. 5.50% of the stock is owned by insiders.
Large investors have recently bought and sold shares of the stock. SG Americas Securities LLC purchased a new stake in shares of Tetraphase Pharmaceuticals in the third quarter worth about $107,000. Cubist Systematic Strategies LLC purchased a new stake in shares of Tetraphase Pharmaceuticals in the third quarter worth about $195,000. Paloma Partners Management Co purchased a new stake in shares of Tetraphase Pharmaceuticals in the fourth quarter worth about $210,000. American International Group Inc. lifted its position in shares of Tetraphase Pharmaceuticals by 44.1% in the third quarter. American International Group Inc. now owns 33,826 shares of the biopharmaceutical company’s stock worth $231,000 after buying an additional 10,345 shares in the last quarter. Finally, Virtus Fund Advisers LLC purchased a new stake in shares of Tetraphase Pharmaceuticals in the fourth quarter worth about $376,000. Institutional investors own 58.50% of the company’s stock.
Tetraphase Pharmaceuticals Company Profile
Tetraphase Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops various antibiotics for the treatment of serious and life-threatening multidrug-resistant infections. The company's lead product candidate is eravacycline, a synthetic fluorocycline intravenous and IV antibiotic for use as a first-line empiric monotherapy to treat resistant and multidrug-resistant infections, including multidrug-resistant Gram-negative infections.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Tetraphase Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tetraphase Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.